Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done?
Granger
Christopher B
CB
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D018943:Anthracyclines / Q000009:adverse effects / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D002317:Cardiovascular Agents / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000187:drug effects / Q000502:physiology; D006801:Humans; D011237:Predictive Value of Tests; D011929:Razoxane / Q000627:therapeutic use; D012307:Risk Factors; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D018943:Anthracyclines; D000970:Antineoplastic Agents; D002317:Cardiovascular Agents; D011929:Razoxane